Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALM-ILD
jRCT2031250506Phase 3Recruiting
- Sponsor
- Insmed Incorporated
- Start
- Jan 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
01
Overview
Phase 3, randomised, double-blind trial in pulmonary hypertension associated with interstitial lung disease (PH-ILD) comparing Treprostinil Palmitil Inhalation Powder with Placebo (2 arms). Primary endpoint: Change in 6-minute walk distance measured at peak exposure from baseline to Week 24. Started Jan 2026; status: recruiting.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Beyond the preview
Go deeper on jRCT2031250506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250506.